In Other News

• FDA Approves Expanded Liquid Biopsy Panel for Advanced Cancer Profiling

• AI-Enabled Assistant Unifies Molecular Workflow Planning and Support

• Strategic Collaboration Advances RNA Foundation Models for Precision Oncology

• Microbial Saliva Test Could Help Triage Esophageal Cancer Risk

• Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk

• Simple Blood Test Could Replace Biopsies for Lung Transplant Rejection Monitoring

• Expanded DPYD Genotyping Test Supports Safer Chemotherapy Dosing

• Partnership Brings Single-Cell Analysis into Clinical Oncology Workflows

• Multi-Omics Profiling Helps Predict BCG Response and Recurrence in Bladder Cancer

• Common White Blood Cells Produce Schizophrenia-Linked Protein

• International Experts Recommend Ending Routine 'Corrected' Calcium Reporting

• New Computational Tool Reveals Genetic Driver of Idiopathic Neuropathy

• Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths

• AI Tool Automates Validation of Laboratory Software Configuration Changes

• Breast Cancer-Specific Signatures Link Genome Instability to Outcomes

• Whole-Genome MRD Test Detects Early Recurrence in Muscle-Invasive Bladder Cancer

• Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer

• FDA-Cleared Genomic Profiling Assay Guides Treatment Selection in Solid Tumors

• Nanopore Method Captures RNA Folding at Single-Molecule Resolution

• ctDNA Blood Test Could Help Guide Radiotherapy in Patients with Limited Metastases

• Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images

• Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors

• FDA-Approved MRD Blood Test Guides Adjuvant Bladder Cancer Therapy